ReviewFrontiers in allergy2026
Age-specific efficacy of biologics in severe asthma: a pediatric perspective.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe pediatric asthma is a rare yet burdensome disease, often unresponsive to conventional anti-asthmatic treatments and associated with significant morbidity, impaired lung development, and high healthcare use. Over the last two decades, biologic therapies have deeply changed the treatment of severe asthma, with both clinical and functional efficacy and a favorable safety profile. However, most studies and clinical trials on the field have focused on adults, leaving a relevant gap in pediatric-specific evidence. Since pediatric responses may deeply diverge from adults due to age-specific immunological and physiological factors, this narrative review aims to summarize current pediatric-specific evidence on the efficacy and safety of Europe-licensed anti-asthmatic biologics for pediatric severe asthma, highlighting key differences from adult data and discussing emerging challenges and future research directions such preventive use of biologics, innovative delivery methods, combination treatments, standardized definitions of asthma remission and development of pediatric-specific outcome measures, ultimately leading to individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.